The Journal of Practical Medicine >

2025 , Vol. 41 >Issue 9: 1273 - 1284

DOI: https://doi.org/10.3969/j.issn.1006-5725.2025.09.002

Feature Reports：Nephrosis

The expression of IQGAP2 in renal cell carcinoma and its effect on the malignant biological behavior of renal cell carcinoma

  • Hao CHEN ,
  • Yunfeng NIU ,
  • Qi WANG ,
  • Ting Lü ,
  • Tao LI ,
  • Kunpeng ZENG ,
  • Bo FAN
Expand
  • Department of Urology，the Fourth Hospital of Hebei Medical University，Shijiazhuang 050035，Hebei，China

Received date: 2025-01-06

  Online published: 2025-05-20

Fold

Abstract

Objective To investigate the expression pattern of IQGAP2 in renal cell carcinoma tissues and cell lines， and to analyze its effects on the proliferation and migration of renal cell carcinoma cells. Methods Firstly， GEO database was used to screen differentially expressed genes between renal cell carcinoma tissues， and GEPIA， TIMER2.0 were used to analyze the expression level of IQGAP2 in renal cell carcinoma tissue. Subsequently， knockdown （siRNA） and overexpression plasmids of IQGAP2 were constructed and transfected into ACHN and 786-O cell lines to perform a series of functional experiments to evaluate the effect of IQGAP2 on the malignant biological behavior of renal carcinoma cells. qRT-PCR and Western Blot were used to detect the expression of EMT （epithelial-mesenchymal transition） related proteins after knockdown and overexpression of IQGAP2. Results In renal cell carcinoma tissues， the relative expression of IQGAP2 was significantly lower than in adjacent normal tissues （P < 0.001）. Transfection of si-IQGAP2 in ACHN and 786-O cells effectively downregulated the mRNA and protein expression levels of IQGAP2 （P < 0.01）， while transfection with an overexpression plasmid significantly upregulated its mRNA and protein expression （P < 0.001）. Further studies revealed that overexpression of IQGAP2 significantly inhibited the proliferation （P < 0.05） and migration （P < 0.01） of ACHN and 786-O cells， whereas knockdown of IQGAP2 enhanced their proliferation （P < 0.05， P < 0.001） and migration （P < 0.01）. Through qRT-PCR and Western blot analyses of EMT-related proteins， it was found that reduced expression of IQGAP2 promoted the epithelial-mesenchymal transition （EMT） process in renal cancer cells. Conclusions The expression of IQGAP2 is low in renal cell carcinoma tissues and cells， and the decrease of the expression level can promote the EMT process of renal cell carcinoma cells， and then enhance the proliferation and migration of renal cell carcinoma cells. IQGAP2 plays an important tumor suppressor role in renal cell carcinoma.

Key words： renal cancer; IQGAP2; 786-O; ACHN; biological behavior

Cite this article

Hao CHEN , Yunfeng NIU , Qi WANG , Ting Lü , Tao LI , Kunpeng ZENG , Bo FAN . The expression of IQGAP2 in renal cell carcinoma and its effect on the malignant biological behavior of renal cell carcinoma[J]. The Journal of Practical Medicine, 2025 , 41(9) : 1273 -1284 . DOI: 10.3969/j.issn.1006-5725.2025.09.002

References

1 CHEN B， LI J， HUANG Y， et al. The role of cytoreductive nephrectomy in metastatic renal cell carcinoma in the targeted therapy and immunological therapy era： A systematic review and meta-analysis ［J］. Int J Surg，2023，109（4）：982-994. doi:10.1097/js9.0000000000000314
2 CAPITANIO U， MONTORSI F. Renal cancer ［J］. Lancet，2016，387（10021）：894-906. doi:10.1016/s0140-6736(15)00046-x
3 LINEHAN W M， RICKETTS C J. The cancer genome atlas of renal cell carcinoma： Findings and clinical implications ［J］. Nat Rev Urol，2019，16（9）：539-552. doi:10.1038/s41585-019-0211-5
4 张明津，付伟金. 纳武单抗治疗晚期肾癌的研究进展［J］. 实用医学杂志，2020，36（23）：3184-3188.
5 SIEGEL R L， MILLER K D， FUCHS H E， et al. Cancer statistics， 2022［J］. CA Cancer J Clin，2022，72（1）：7-33. doi:10.3322/caac.21708
6 HEDMAN AC， SMITH J M， SACKS D B. The biology of IQGAP proteins： Beyond the cytoskeleton ［J］. EMBO Rep，2015，16（4）：427-446. doi:10.15252/embr.201439834
7 THINES L， ROUSHAR F J， HEDMAN A C， et al. The IQGAP scaffolds： Critical nodes bridging receptor activation to cellular signaling ［J］. J Cell Biol，2023，222（6）：e202205062. doi:10.1083/jcb.202205062
8 WHITE C D， BROWN M D， SACKS D B. IQGAPs in cancer： a family of scaffold proteins underlying tumorigenesis ［J］. FEBS Lett，2009，583（12）：1817-1824. doi:10.1016/j.febslet.2009.05.007
9 SMITH J M， HEDMAN A C， SACKS D B. IQGAPs choreograph cellular signaling from the membrane to the nucleus ［J］. Trends Cell Biol，2015，25（3）：171-184. doi:10.1016/j.tcb.2014.12.005
10 WEI T， LAMBERT P F. Role of IQGAP1 in carcinogenesis ［J］. Cancers （Basel），2021，13（16）：3940. doi:10.3390/cancers13163940
11 SONG F， DAI Q， GRIMM M O， et al. The antithetic roles of IQGAP2 and IQGAP3 in cancers ［J］. Cancers （Basel），2023，15（4）：1115. doi:10.3390/cancers15041115
12 BRILL S， LI S， LYMAN C W， et al. The ras GTPase-activating-protein-related human protein IQGAP2 harbors a potential actin binding domain and interacts with calmodulin and rho family GTPases ［J］. Mol Cell Biol，1996，16（9）：4869-4878. doi:10.1128/mcb.16.9.4869
13 CUPIT L D， SCHMIDT V A， MILLER F， et al. Distinct PAR/IQGAP expression patterns during murine development： Implications for thrombin-associated cytoskeletal reorganization ［J］. Mamm Genome，2004，15（8）：618-629. doi:10.1007/s00335-004-2370-8
14 KUMAR D， PATEL S A， HASSAN M K， et al. Reduced IQGAP2 expression promotes EMT and inhibits apoptosis by modulating the MEK-ERK and p38 signaling in breast cancer irrespective of ER status ［J］. Cell Death Dis，2021，12（4）：389. doi:10.1038/s41419-021-03673-0
15 WANG D， WANG Z， ZHANG L， et al. LncRNA PDCD4-AS1 alleviates triple negative breast cancer by increasing expression of IQGAP2 via miR-10b-5p ［J］. Transl Oncol，2021，14（1）：100958. doi:10.1016/j.tranon.2020.100958
16 KUMAR D， PATEL S A， KHAN R， et al. Iq motif-containing GTPase-Activating Protein 2 Inhibits breast cancer angiogenesis by suppressing VEGFR2-AKT signaling ［J］. Mol Cancer Res，2022，20（1）：77-91. doi:10.1158/1541-7786.mcr-20-1044
17 SONG F， KOTOLLOSHI R， GAJDA M， et al. Reduced IQGAP2 promotes bladder cancer through regulation of MAPK/ERK pathway and cytokines ［J］. Int J Mol Sci，2022，23（21）：13508. doi:10.3390/ijms232113508
18 SCHMIDT V A， CHIARIELLO C S， CAPILLA E， et al. Development of hepatocellular carcinoma in Iqgap2-deficient mice is IQGAP1 dependent［J］. Mol Cell Biol，2008，28（5）：1489-1502. doi:10.1128/mcb.01090-07
19 DENG Z， WANG L， HOU H， et al. Epigenetic regulation of IQGAP2 promotes ovarian cancer progression via activating Wnt/β-catenin signaling ［J］. Int J Oncol，2016，48（1）：153-160. doi:10.3892/ijo.2015.3228
20 XIE Y， ZHENG L， TAO L. Downregulation of IQGAP2 correlates with prostate cancer recurrence and metastasis ［J］. Transl Oncol，2019，12（2）：236-244. doi:10.1016/j.tranon.2018.10.009
21 XU L， SHAO Y， REN L， et al. IQGAP2 inhibits migration and invasion of gastric cancer cells via elevating SHIP2 phosphatase activity ［J］. Int J Mol Sci，2020，21（6）：1968. doi:10.3390/ijms21061968
22 MANINI C， LóPEZ-FERNáNDEZ E， LARRINAGA G， et al. Clear cell renal cell carcinoma： A test bench for investigating tumor complexity ［J］. Cancers （Basel），2024，16（4）：829. doi:10.3390/cancers16040829
23 BARATA P， GULATI S， ELLIOTT A， et al. Renal cell carcinoma histologic subtypes exhibit distinct transcriptional profiles ［J］. J Clin Invest，2024，134（11）：e178915. doi:10.1172/jci178915
24 KATDARE K A， KJAR A， O'BROWN N M， et al. IQGAP2 regulates blood-brain barrier immune dynamics ［J］. bioRxiv ［Preprint］，2024：2023.02.07.527394.doi： 10.1101/2023.02.07. 527394 .
25 TAN D， MIAO D， ZHAO C， et al. N6-methyladenosine-modified ALDH9A1 modulates lipid accumulation and tumor progression in clear cell renal cell carcinoma through the NPM1/IQGAP2/AKT signaling pathway ［J］. Cell Death Dis，2024，15（8）：635. doi:10.1038/s41419-024-06896-z
26 ZHANG J， YANG G， ZHA X， et al. Polymorphisms within the IQGAP2 and CRTAC1 genes of gannan yaks and their association with milk quality characteristics ［J］. Foods，2024，13（23）：3720. doi:10.3390/foods13233720
27 RAMAMOORTHY K， SABUI S， KIM G， et al. IQGAP-2： a novel interacting partner with the human colonic thiamin pyrophosphate transporter ［J］. Am J Physiol Cell Physiol，2024，327（6）：C1451-C1461. doi:10.1152/ajpcell.00484.2024
28 ZHANG Y E， STUELTEN C H. Alternative splicing in EMT and TGF-β signaling during cancer progression ［J］. Semin Cancer Biol，2024，101：1-11. doi:10.1016/j.semcancer.2024.04.001
29 BRACKEN C P， GOODALL G J， GREGORY P A. RNA regulatory mechanisms controlling TGF-β signaling and EMT in cancer ［J］. Semin Cancer Biol，2024，106-107：13-14. doi:10.1016/j.semcancer.2024.08.005
30 KHAN A Q， HASAN A， MIR S S， et al. Exploiting transcription factors to target EMT and cancer stem cells for tumor modulation and therapy ［J］. Semin Cancer Biol，2024，100：1-16. doi:10.1016/j.semcancer.2024.03.002
Options
Outlines

/

〈 〉